Meritage Portfolio Management Has $5.31 Million Stock Position in GSK plc (NYSE:GSK)

Meritage Portfolio Management cut its stake in shares of GSK plc (NYSE:GSK) by 1.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 157,102 shares of the pharmaceutical company’s stock after selling 2,544 shares during the period. Meritage Portfolio Management’s holdings in GSK were worth $5,313,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its position in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Primecap Management Co. CA grew its stake in shares of GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after acquiring an additional 342,365 shares in the last quarter. Provident Trust Co. increased its position in GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after acquiring an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC raised its stake in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Down 0.2 %

NYSE GSK opened at $34.84 on Wednesday. The business has a fifty day moving average price of $34.10 and a two-hundred day moving average price of $37.60. The stock has a market capitalization of $72.22 billion, a PE ratio of 22.63, a PEG ratio of 1.38 and a beta of 0.64. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. Equities analysts expect that GSK plc will post 3.92 earnings per share for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.